Company Overview of Khandelwal Laboratories Pvt.Ltd.
Khandelwal Laboratories Pvt.Ltd. manufactures and markets oncology products. It offers ANAFORTAN Group, a combination with camylofin DiHCl antispasmodic; ROBI Group, a combination with methocarbamol muscle relaxants; CEFI Group, a combination of cefixime antibiotic; and PRENOXID, a prenoxdiazine HCl antitussive. The company also provides generic products anaesthetics, anthelmintic, anti hypertensives, anti-ulcler agents, anti-asthamatic, anti-diabetic, anti-fungal, anti-histamines, anti-microbials, anti-tussives, drugs in osteoporosis, haematinic and nutritional supplement, NSAIDs, and skeletal muscle relaxants. In addition, it offers chiral intermediates, including monosaccharides derivativ...
Mumbai, 400 033
Founded in 1945
Key Executives for Khandelwal Laboratories Pvt.Ltd.
Chairman of the Board and Managing Director
Compensation as of Fiscal Year 2016.
Khandelwal Laboratories Pvt.Ltd. Key Developments
Khandelwal Laboratories Receives Approval of the Product Licenses for Zestra Zestra Glide, Ejectdelay and Sensum from the Indian FDA
Aug 19 16
Khandelwal Laboratories announced that its has received the approval of the product licenses for Zestra Zestra Glide, EjectDelay and Sensum from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India. Zestra is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra is the first Natural Health Product to receive approval for the indication of FSI/AD in Canada as an NHP.
Innovus Pharmaceuticals, Inc. Enters into Marketing and Distribution Agreement with Khandelwal Laboratories
Sep 10 15
Innovus Pharmaceuticals, Inc. announced it has entered into an marketing and distribution agreement with Khandelwal Laboratories under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma’s products including Zestra® to increase Female Sexual Arousal, Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide® the high viscosity water based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. This deal has been facilitated by Nortons (UK). Under the agreement, the minimum orders for the first term of the agreement are over $2.6 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|